The technical genesis and practice of 8-aminoquinoline therapy of latent malaria offer
singular scientific, clinical, and public health insights. The 8-aminoquinolines brought …

Primaquine is an antimalarial drug of the 8-aminoquinoline class. It has prophylactic activity,
relatively weak schizontocidal activity and radical curative activity in Plasmodium vivax and …

Malaria elimination will be possible only with serious attempts to address asymptomatic
infection and chronic infection by both Plasmodium falciparum and Plasmodium vivax …

Malaria remains an important cause of global morbidity and mortality. As antimalarial drug
resistance escalates, new safe and effective medications are necessary to prevent and treat …

Oxidative agents can cause acute haemolytic anaemia in persons with G6PD deficiency.
Understanding the relationship between G6PD genotype and the phenotypic expression of …

Abstract Glucose-6-phosphate dehydrogenase (G6PD) is a potentially pathogenic inherited
enzyme abnormality and, similar to other human red blood cell polymorphisms, is …

Despite declining global malaria incidence, the disease continues to be a threat to people
living in endemic regions. In 2015, an estimated 214 million new malaria cases and 438,000 …

There is a pressing need for compounds with broad-spectrum activity against malaria
parasites at various life cycle stages to achieve malaria elimination. However, this goal …

The cure of patients with Plasmodium vivax malaria requires killing both the asexual stages
of the parasites in the blood as well as the dormant liver stages (hypnozoites)—together …

The diagnosis and management of glucose-6-phosphate dehydrogenase (G6PD) deficiency
is a crucial aspect in the current phases of malaria control and elimination, which will require …